Cesar Alaniz is is a Clinical Associate Professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy and a clinical pharmacist for the adult medical intensive care unit in the University of Michigan Hospitals and Health Centers (UMHHC). He serves on a variety of committees within UMHHC and the College of Pharmacy. His principal area of research is in critical care phamacotherapy.
Mohammad RA, Regal R, Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother. 2012; 46:1559-63.
Alaniz C, Pogue JM. Vancomycin versus linezolid in the treatment of methicillin-resistant staphylococcus aureus pneumonia: implications of the zephyr trial. Ann Pharmacother. 2012;46:1432-45.
Miller JT, Welage LS, Kraft MD, Alaniz C. Does body weight impact the efficacy of vasopressin in the management of septic shock? J Crit Care. 2012;27:289-93.
Pettit RS, Zimmerman CR, Alaniz C, Dorsch MP. Cost analysis before and after implementation of a computerized physician order entry form for enoxaparin. P T. 2012;37:107-11.
Alaniz C, Hyzy RC. Albumin meta-analysis and epochs of care. Crit Care Med. 2011;39:1852.